Investors & Media

Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease

Builds on existing collaboration with Novartis for pelacarsen, which is currently being evaluated in a Phase 3 cardiovascular outcome study with data expected in 2025 Ionis’ new and advanced technologies will be used to create next generation compound targeting Lp(a) Ionis will receive a $60

Read more
You are now leaving https://www.ionis.com to visit